Newer triazole antifungal agents: Pharmacology, spectrum, clinical efficacy and limitations

Expert Opinion on Investigational Drugs

Volumn 15, Issue 6, 2006, Pages 579-602

  Aperis, George ^a   Mylonakis, Eleftherios ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Albaconazole; Aspergillosis; Aspergillus spp.; Candida spp.; Candidaemia; Candidiasis; Coccidioidomycosis; Cryptococcal meningitis; Fusariosis; histoplasmosis; Posaconazole; Ravuconazole; Scedosporiasis; UK 109,496, UR 9825; Voriconazole; Zygomycosis

Indexed keywords

ALBACONAZOLE; AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; BMS 379224; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; E 1224; ECHINOCANDIN; EFAVIRENZ; ERGOT ALKALOID; FLUCONAZOLE; ITRACONAZOLE; LIVER ENZYME; MICAFUNGIN; PIMOZIDE; PLACEBO; POSACONAZOLE; RAPAMYCIN; RAVUCONAZOLE; RAVUCONAZOLE DILYSINE PHOSPHOESTER; RIFABUTIN; RIFAMPICIN; RITONAVIR; TERFENADINE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ABNORMAL VISION; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; BLURRED VISION; BREAST FEEDING; CANDIDIASIS; CHILL; CHROMOMYCOSIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COLOR VISION DEFECT; CONSTIPATION; CROSS RESISTANCE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FEVER; FUNGAL MENINGITIS; FUNGICIDAL ACTIVITY; HALLUCINATION; HEADACHE; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOTENSION; IN VITRO STUDY; LACTOSE INTOLERANCE; LIVER DYSFUNCTION; LUNG ASPERGILLOSIS; MACULOPAPULAR RASH; MALAISE; MINIMUM INHIBITORY CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; MUCORMYCOSIS; MYCETOMA; MYCOSIS; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PHAEOHYPHOMYCOSIS; PHARMACODYNAMICS; PHOTOPHOBIA; PREGNANCY; PRURITUS; QT PROLONGATION; SALVAGE THERAPY; SKIN TOXICITY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SURVIVAL; TACHYCARDIA; TOENAIL ONYCHOMYCOSIS; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT RESPONSE; URINE INCONTINENCE; VAGINA CANDIDIASIS; VISUAL DISORDER; VOMITING; XEROSTOMIA;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; HUMANS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; THIAZOLES; TRIAZOLES;

EID: 33745234214     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.6.579     Document Type: Article

References (174)

1. HOSSAIN MA, GHANNOUM MA: New investigational antifungal agents for treating invasive fungal infections. Expert Opin. Invest. Drugs (2000) 9(8):1797-8813.
2. KONTOYIANNIS DP, HARE R, SOLOMON H et al.: Posaconazole is highly effective as a second-line agent in zygomycosis: summary of 91 cases. 45th International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (16-19 December 2005).
3. BARTROLI X: A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis. 45th International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (16-19 December 2005).
4. JOHNSON LB, KAUFFMAN CA: Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. (2003) 36(5):630-637.
5. GOTHARD P, ROGERS TR: Voriconazole for serious fungal infections. Int. J. Clin. Pract. (2004) 58(1):74-80.
6. PEARSON MM, ROGERS PD, CLEARY JD, CHAPMAN SW: Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. (2003) 37(3):420-432.
7. COURTNEY R, PAI S, LAUGHLIN M, LIM J, BATRA V: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. (2003) 47(9):2788-2795.
8. COURTNEY R, RADWANSKI E, LIM J, LAUGHLIN M: Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. (2004) 48(3):804-808.
9. COURTNEY R, WEXLER D, RADWANSKI E, LIM J, LAUGHLIN M: Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults, Br. J. Clin. Pharmacol. (2004) 57(2):218-222.
10. GRACELA DM, OLSEN SJ, MUMMANENI V et al.: Ravuconazole: multiple ascending oral dose study in healthy subjects. 40th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (17-20 September 2000).
11. OLSEN SJ, MUMMANENI V, ROLAN P, NORTON I, GRASELA DM: Ravuconazole single ascending oral dose study in healthy subjects. 40th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (17-20 September 2000).
12. GROLL AH, MICKIENE D, PETRAITIS V et al.: Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. J. Antimicrob. Chemother. (2005) 56(5):899-907.
13. PETRAITIENE R, PETRAITIS V, LYMAN CA et al.: Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (2004) 48(4):1188-1196.
14. BARTROLI J, TURMO E, ALGUERO M et al.: New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. J. Med. Chem. (1998) 41(11):1869-1882.
15. CAPILLA J, YUSTES C, MAYAYO E et al.: Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits. Antimicrob. Agents Chemether. (2003) 47(6):1948-1951.
16. DONNELLY JP, DE PAUW BE: Voriconazole - a new therapeutic agent with an extended spectrum of antifungal activity. Clin. Microbiol. Infect. (2004) 10(Suppl. 1): 107-117.
17. PURKINS L, WOOD N, GHAHRAMANI P et al.: Pharmacokinetics and safety of voriconazole following intravenous to oral-dose escalation regimens. Antimicrob. Agents Chemother. (2002) 46(8):2546-2553.
18. HOFFMAN HI., RATHBUN RC: Review of the safety and efficacy of voriconazole. Expert Opin. Investig. Drugs (2002) 11:409-429.
19. TRIFILIO S, ORTIZ R, PENNICK G et al.: Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2005) 35(5):509-513.
20. HARIPRASAD SM, MIELER WF, HOLZ ER et al.: Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol. (2004) 122(1):42-47.
21. 14C posaconazole following oral administration in healthy male subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (27-30 September 2002).
22. EZZET F, WEXLER D, COURTNEY R et al.: Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet. (2005) 44(2):211-220.
23. GUPTA AK, LEONARDI C, STOLTZ RR, PIERCE PF, CONETTA B: A Phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J. Eur. Acad. Dermatol. Venereol. (2005) 19(4):437-443.
24. ESPINEL-INGROFF A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. (2003) 20(4):121-136.
25. PFALLER MA, MESSER SA, BOYKEN L et al.: Cross-resistance between fluconazole and ravuconazole and die use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol. (2004) 42(7):3137-3141.
26. FUNG-TOMC JC, HUCZKO E, MINASSIAN B, BONNER DP: In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. (1998) 42(2):313-318.
27. RAMOS G, CUENCA-ESTRELLA M, MONZON A, RODRIGUEZ-TUDELA JL: In-vitro comparative activity of UR-9825. itraconazole and fluconazole against clinical isolates of Candida spp. J. Antimicrob. Chemother. (1999) 44:283-286.
28. CUENCA-ESTRELLA M, GOMEZ-LOPEZ A, MELLADO, E, GARCIA-EFFRON G, RODRIGUEZ-TUDELA JL: In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob. Agents Chemother. (2004) 48(8):3107-3111.
29. PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN, DIEKEMA DJ: In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. (2002) 46(6):1723-1727.
30. LAVERDIERE M, RESTIERI C, HABEL F: Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods. Int. J. Antimicrob. Agents (2002) 20(6):468-471.
31. TAWARA S, IKEDA F, MAKI K et al.: In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. (2000) 44(1):57-62.
32. UZUN O, KOCAGOZ S, CETINKAYA Y, ARIKAN S, UNAL S: In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. (1997) 41(5):1156-1157.
33. ZHANEL GG, KARLOWSKY JA, HARDING GA et al.: In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. (1997) 41(4):863-865.
34. BARTIZAL K, GILL CJ, ABRUZZO GK et al: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41(11):2326-2332.
35. MULLER FM, KURZAI O, HACKER J, FROSCH M, MUHLSCHLEGEL F: Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. J Antimicrob. Chemother. (2001) 48(5):713-715.
36. OSTROSKY-ZEICHNER L, REX JH, PAPPAS PG et al.: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. (2003) 47(10):3149-3154.
37. ZHANEL GG, KARLOWSKY JA, ZELENITSKY SA, TURIK MA, HOBAN DJ: Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents. Antimicrob. Agents Chemother. (1998) 42(9):2446-2448.
38. LAVERDIERE M, HOBAN D, RESTIERI C, HABEL F: In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J. Antimicrob. Chemother. (2002) 50(1):119-123.
39. VAZQUEZ JA, LYNCH M, BOIKOV D, SOBEL JD: In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and resistant Candida species. Antimicrob. Agents Chemother. (1997) 41(7):1612-1614.
40. MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. (1998) 32(1):33-37.
41. MIKAMO H, SATO Y, TAMAYA T: In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother. (2000) 46(3):485-487.
42. PFALLER MA, MESSER SA, COFFMAN S: In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. (1997) 41(4):763-766.
43. CHAVEZ M, BERNAL S, VALVERDE A et al.: In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J. Antimicrob. Chemother. (1999) 44(5):697-700.
44. ZAOUTIS TE, FORAKER E, McGOWAN KL et al.: Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn. Microbiol. Infect. Dis. (2005) 52(4):295-298.
45. CUENCA-ESTRELLA M, RODRIGUEZ D, ALMIRANTE B et al.: In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J. Antimicrob. Chemother. (2005) 55(2):194-199.
46. KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Crytococcus neoformans. Antimicrob. Agents Chemother. (1997) 41(9):1957-1960.
47. UCHIDA K, NISHIYAMA Y, YOKOTA N, YAMAGUCHI H: In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J. Antibiot. (Tokyo) (2000) 53(10):1175-1181.
48. PFALLER MA, DIEKEMA DJ, MESSER SA, HOLLIS RJ, JONES RN: In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. (2003) 47(3):1068-1071.
49. PFALLER MA, DIEKEMA DJ, RINALDI MG et al.: Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol. (2005) 43(12):5848-5859.
50. ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. (1998) 36(10):2950-2956.
51. PFALLER MA, JONES RN, DOERN GV et al.: International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn. Microbiol. Infect. Dis. (1999) 35(1):19-25.
52. CHRYSSANTHOU E, CUENCA-ESTRELLA M: Comparison of the antifungal susceptibility testing subcommittee of the European committee on antibiotic susceptibility testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. (2002) 40(10):3841-3844.
53. MARCO F, DANES C, ALMELA M et al.: Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn. Microbiol. Infect. Dis. (2003) 46(4):259-264.
54. HEYN K, TREDUP A, SALVENMOSER S, MULLER FM: Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp, and Fusarium solani. Antimicrob. Agents Chemother. (2005) 49(12):5157-5159.
55. QUINDOS G, CARRILLO-MUNOZ AJ, AREVALO MP et al.: In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy (2000) 46(6):395-401.
56. PFALLER MA, MESSER SA, GEE S et al.: In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin. Microbiol. (1999) 37(3):870-872.
57. AREVALO MP, CARRILLO-MUNOZ AJ, SALGADO J et al: Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob. Chemother. (2003) 51(1):163-166,
58. BARCHIESI F, SCHIMIZZI AM, FOTHERGILL AW, SCALISE G, RINALDI MG: In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. J. Clin. Microbiol Infect. Dis. (1999) 18(4):302-304.
59. PFALLER MA, DIEKEMA DJ, MESSER SA et al.: In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn. Microbiol. Infect. Dis. (2004) 48(2):101-105.
60. ERNST EJ, ROLING EE, PETZOLD CR, KEELE DJ, KLEPSER ME: In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother (2002) 46(12):3846-3853.
61. PFALLER MA, MESSER SA, BOYKEN L et al.: Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin. Microbiol. (2004) 42(7):3142-3146.
62. GHANNOUM MA, OKOGBULE-WONODI I, BHAT N, SANATI H: Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. J. Chemother. (1999) 11(1):34-39.
63. CACCIAPUOTI A, LOEBENBERG D, CORCORAN E et al.: In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. (2000) 44(8):2017-2022.
64. CLEMONS KV, STEVENS DA: Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob. Agents Chemother. (2001) 45(12):3433-3436.
65. CAPILLA J, ORTONEDA M, PASTOR FJ, GUARRO J: In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob. Agents Chemother. (2001) 45(9):2635-2637.
66. ESPINEL-INGROFF A: Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. (2003) 41(1):403-409.
67. GUINEA J, PELAEZ T, ALCALA L, RUIZ-SERRANO MJ, BOUZA E: Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation. Antimicrob. Agents Chemother. (2005) 49(8):3495-3497.
68. MOORE CB, WALLS CM, DENNING DW: In vitro activity of the new triazole BMS-207147 against Aspegillus species in comparison with itraconazole and amphotericin B. Antimicrob. Agents Chemother. (2000) 44(2):441-443.
69. PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. (2002) 46(4):1032-1037.
70. NAKAI T, UNO J, OTOMO K et al.: In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy (2002) 48(2):78-81.
71. OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. (1998) 42(10):2726-2730.
72. DIEKEMA DJ, MESSER SA, HOLLIS RJ, JONES RN, PFALLER MA: Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol, (2003) 41(8):3623-3626.
73. SERRANO MDEL C, VALVERDE-CONDE A, CHAVEZ MM et al.: In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn. Microbiol. Infect. Dis. (2003) 45(2):131-135.
74. PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. (1998) 30(4):251-255.
75. CHANDRASEKAR PH, CUTRIGHT J, MANAVATHU E: Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J. Antimicrob. Chemother. (2000) 45(5):673-676.
76. IMAI JK, SINGH G, CLEMONS KV, STEVENS DA: Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob. Agents Chemother. (2004) 48(10):4063-4066.
77. KIRKPATRICK WR, PEREA S, COCO BJ, PATTERSON TF: Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J. Antimicrob. Chemother. (2002) 49(2):353-357.
78. MILLER JL, SCHELL WA, WILLS EA et al: In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother. (2004) 48(2):384-387.
79. YILDIRAN ST, SARACLI MA, FOTHERGILL AW, RINALDI MG: In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole. Eur. J. Clin. Microbiol. Infect. Dis (2000) 19(4):317-319.
80. MORERA-LOPEZ Y, TORRES-RODRIGUEZ JM, JIMENEZ-CABELLO T, BARO-TOMAS T: Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med. Mycol. (2005) 43(6):505-510.
81. PERKINS A, GOMEZ-LOPEZ A, MELLADO E, RODRIGUEZ-TUDELA JL, CUENCA-ESTRELLA M: Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J. Antimicrob. Chemother (2005) 56(6):1144-1147.
82. PFALLER MA, MESSER SA, BOYKEN L et al: Global trends in the antifungal susceptibility of Cryptococcus neaformans (1990 to 2004). J. Clin. Microbiol. (2005) 43(5):2163-2167.
83. CHANDENIER J, ADOU-BRYN KD, DOUCHET C et al.: In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23(6):506-508.
84. PERFECT JR, COX GM, DODGE RK, SCHELL WA: In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. (1996) 40(8):1910-1913.
85. HATA K, KIMURA J, MIKI H et al.: In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob. Agents Chemother. (1996) 40(10):2237-2242.
86. DANNAOUI E, MELETIADIS J, MOUTON JW, MEIS JF, VERWEIJ PE: In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. (2003) 51(1):45-52.
87. MINASSIAN B, HUCZKO E, WASHO T, BONNER D, FUNG-TOMC J: In vitro activity of ravuconazole against zygomycetes, Scedosporium and Fusarium isolates. Clin. Microbiol. Infect. (2003) 9(12):1250-1252.
88. SUN QN, FOTHERGILL AW, McCARTHY DI, RINALDI MG, GRAYBILL JR: In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. (2002) 46(5):1581-1582.
89. PAPHITOU NI, OSTROSKY-ZEICHNER L, PAETZNICK VL et al.: In vitro antifungal susceptibilities of Trichosporon species. Antimicrob. Agents Chemother. (2002) 46(4):1144-1146.
90. MELETIADIS J, MEIS JF, MOUTON JW et al.: In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob. Agents Chemother. (2002) 46(1):62-68.
91. CARRILLO AJ, GUARRO J: In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. (2001) 45(7):2151-2153.
92. GONZALEZ GM, FOTHERGILL AW, SUTTON DA, RINALDI MG, LOEBENBERG D: In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med. Mycol. (2005) 43(3):281-284.
93. SERENA C, MARINE M, PASTOR FJ, NOLARD N, GUARRO J: In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Tichosporon, Sporobolomyces and Rhodotorula. J. Antimicrob. Chemother. (2005) 55(6):1020-1023.
94. LI RK, CIBLAK MA, NORDOFF N et al: In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother. (2000) 44(6):1734-1736.
95. SUGAR AM, LIU XP: In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob. Agents Chemother. (1996) 40(5):1314-1316.
96. ESPINEL-INGROFF A: In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol (1998) 36(1):198-202.
97. GONZALEZ GM, TIJERINA R, NAJVAR LK et al.: In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob. Agents Chemother. (2002) 46(5):1352-1356.
98. ORTONEDA M, CAPILLA J, PASTOR FJ et al.: In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob. Agents Chemother. (2004) 48(7):2727-2729.
99. GOMEZ-LOPEZ A, MELLADO E, RODRIGUEZ-TUDELA JL, CUENCA-ESTRELLA M: Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J. Antimicrob. Chemother. (2005) 55(3):312-316.
100. ZAAS AK, BOYCE M, SCHELL W et al.: Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J. Clin. Microbiol. (2003) 41(11):5233-5235.
101. DANNAOUI E, MEIS JF, LOEBENBERG D, VERWEIJ PE: Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. (2003) 47(11):3647-3650.
102. AL-ABDELY HM, NAJVAR LK, BOCANEGRA R, GRAYBILL JR: Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob. Agents Chemother. (2005) 49(5):1701-1707.
103. AL-ABDELY HM, NAJVAR L, BOCANEGRA R et al.: SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ('Ramichloridium mackenziei'). Antimicrob. Agents Chemother. (2000) 44(5):1159-1162.
104. LUTZ JE, CLEMONS KV, ARISTIZABAL BH, STEVENS DA: Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother. (1997) 41(7):1558-1561.
105. CLEMONS KV, MARTINEZ M, CALDERON L, STEVENS DA: Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. Antimicrob. Agents Chemother. (2002) 46(3):922-924.
106. PERFECT JR, MARR KA, WALSH TJ et al.: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. (2003) 36(9):1122-1131.
107. KULLBERG BJ, SOBEL JD, RUHNKE M et al.: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 366(9495):1435-1442.
108. OSTROSKY-ZEICHNER L, OUDE LASHOF AM, KULLBERG BJ, REX JH: Voriconazole salvage treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. (2003) 22(11):651-655.
109. ALLY R, SCHURMANN D, KREISEL W et al.: A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. (2001) 33(9):1447-1454.
110. HEGENER P, TROKE PF, FATKENHEUER G, DIEHL V, RUHNKE M: Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS (1998) 12(16):2227-2228.
111. HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. (2002) 347(6):408-415.
112. WALSH TJ, PAPPAS P, WINSTON DJ et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. (2002) 346(4):225-234.
113. WALSH TJ, FINBERG RW, ARNDT C et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. (1999) 340(10):764-771.
114. PRENTICE HG, HANN IM, HERBRECHT R et al.: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. (1997) 98(3):711-718.
115. MARR KA: Empirical antifungal therapy-new options, new tradeoffs. N. Engl. J. Med. (2002) 346(4):278-280.
116. POWERS JH, DIXON CA, GOLDBERGER MJ: Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N. Engl. J. Med. (2002) 346(4):289-290.
117. WALSH TJ, LEE J, DISMUKES CA: Decisions about voriconazole versus liposomal amphotericin B (correspondence). N. Engl. J. Med. (2002) 346(19):1499.
118. JOHNSON JR, ULIMANN A, HEUSSEL CP et al.: Voriconazole versus liposomal amphotericin B for empirical antifungal therapy (correspondence). N. Engl. J. Med. (2002) 346(22):1745-1747.
119. RAAD I, BRADSHER R, MORRISON V et al.: Posaconazole salvage therapy for invasive fungal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (October 30 - November 2 2004).
120. GREENBERG RN, HACHEM R, LANGSTON A et al.: Posaconazole therapy for refractory invasive zygomycosis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (14 - 17 September 2003).
121. HACHEM RY, RAAD I, AFIF C et al.: An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SHC56592) in the treatment of invasive fungal infections refractory or intolerant to standard therapy. 40th Interscience Conference on Antimicrobial Agents and Chemptherapy, Toronto, ON, Canada (17 - 20 September 2000).
122. PITISUTTITHUM P, NEGRONI R, GRAYBILL JR et al.: Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. (2005).
123. WALSH TJ, PATTERSON T, LANGSTON A et al.: Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an externally controlled blinded trial. Blood (2003) 102:105a-106a.
124. SEGAL BH, BARNHART LA, ANDERSON VL et al.: Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin. Infect. Dis. (2005) 40(11):1684-1688.
125. BLUMER J, HARE R, KRISHNA G et al.: Efficacy of posaconazole salvage therapy in pediatric subjects with invasive fungal infections. 15th European Congress for Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark (2005).
126. VAZQUEZ JA, NORTHLAND R., MILLER S et al.: Posaconazole compared to fluconazole for oral candidiasis in HIV-posidve patients. 40th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (17 - 20 September 2000).
127. NIETO L, NORTHLAND R, PITTISUTTITHUM P et al.: Posaconazole equivalent to fluconazole in treatment of oropharyngeal candidiasis. 40th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (17 - 20 September 2000).
128. RESTREPO A, CLARK B, GRAHAM DR et al.: Successful treatment of disseminated and acute pulmonary histoplasmosis with posaconazole. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (14 - 17 September 2003).
129. DUPONT B, WEINBRECK P, BRUGIERE C, WINTER C, LAHOULOU R: Effect of posaconazole salvage therapy in five patients with zygomycosis. 15th European Congress for Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark (2005).
130. DUPONT B: Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy. Transplantation (2005) 80(4):544-545.
131. GILMAN AL, SERRANO A, SKELLEY J, ZWICK D: Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant. Pediatr. Blood Cancer (2005)
132. LEATHER HL, CORRELL TA, MEYER CL, SCHMALFUSS IM, WINGARD JR: Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia. Clin. Adv. Hematol. Oncol. (2005) 3(10):773-777.
133. VAZQUEZ JA: Review of treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia. Clin. Adv. Hematol. Oncol. (2005) 3(10):777-778.
134. TOBON AM, ARANGO M, FERNANDEZ D, RESTREPO A: Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis. (2003) 36(11):1488-1491.
135. CHEN A, SOBEL JD: Emerging azole antifungals. Expert Opin. Emerg. Drugs (2005) 10(1):21-33.
136. BEALE M Q-TF, BANHEGYI D, LI N, PIERCE PF: Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (22 - 25 September 2001).
137. DENNING DW, GRIFFITHS CE: Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin. Exp. Dermatol. (2001) 26(8):648-653.
138. GRAYBILL JR, RAAD I, NEGRONI R et al.: Posaconazole long-term safety in subjects with invasive fungal infections. 44th Interscience Conference an Antimicrobial Agents and Chemotherapy, Washington, DC, USA (October 30 - November 2 2004).
139. GROLL AH, WALSH TJ: Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti-Infect. Ther. (2005) 3(4):467-487.
140. LEWIS J, ANSTEAD G, GRAYBILL J: Successful treatment of disseminated coccidioidomycosis (Coccidioides immitis) with posaconazole. 15th Congress of the International Society for Human and Animal Mycosis, San Antonio, USA (25 - 29 May 2003).
141. NEGRONI R, HELOU S, PETRI N et al.: Successful posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera: a case report. 15th Congress of the International Society for Human and Animal Mycosis, San Antonio, USA (25 - 29 May 2003).
142. AL-ABDELY HM, ALKUNAIZI A, AL-TAWFIQ JA et al.: Successful treatment of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with a new triazole, posaconazole (SCH 56592). 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, Scotland (10 - 13 May 2003).
143. MELLINGHOFF IK, WINSTON DJ, MUKWAYA G, SCHILLER GJ: Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin. Infect. Dis. (2002) 34(12):1648-1650.
144. MOUDGAL VV, SOBEL JD: Antifungal drugs in pregnancy: a review. Expert Opin. Drug Saf. (2003) 2(5):475-483.
145. TORRES HA, HACHEM RY, CHEMALY RF, KONTOYIANNIS DP, RAAD II: Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. (2005) 5(12):775-785.
146. GOSBELL IB, TOUMASATOS V, YONG J et al.: Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses (2003) 46(5-6):233-236.
147. HOWDEN BP, SLAVIN MA, SCHWARER AP, MIJCH AM: Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur. J. Clin. Microbiol. Infect. Dis. (2003) 22(2):111-113.
148. STEINBACH WJ, SCHELL WA, MILLER JL, PERFECT JR: Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J. Clin. Microbiol (2003) 41(8):3981-3985.
149. GERZENSHTEIN L, PATEL SM, SCARSI KK, POSTELNICK MJ, FLAHERTY JP: Breakthrough Candida infections in patients receiving voriconazole. Ann. Pharmacother (2005) 39(7-8):1342-1345.
150. ALEXANDER BD, SCHELL WA, MILLER JL, LONG GD, PERFECT JR: Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation (2005) 80(6):868-871.
151. PAVIE J, LACROIX C, HERMOSO DG et al.: Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J. Clin. Microbiol. (2005) 43(9):4902-4904.
152. KONTOYIANNIS DP, LIONAKIS MS, LEWIS RE et al.: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect, Dis. (2005) 191(8):1350-1360.
153. OREN I: Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin. Infect. Dis. (2005) 40(5):770-771.
154. VIGOUROUX S, MORIN O, MOREAU P et al.: Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin. Infect. Dis. (2005) 40(4): e35-e37.
155. LIONAKIS MS, KONTOYIANNIS DP: Sinus zygomycosis in a patient receiving voriconazole prophylaxis. Br. J. Haematol. (2005) 129(1):2.
156. KOBAYASHI K, KAMI M, MURASHIGE N et al:. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica (2004) 890(11):ECR42.
157. SIWEK GT, DODGSON KJ, DE MAGALHAES-SILVERMAN M et al.: Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin. Infect. Dis. (2004) 39(4):584-587.
158. MARTY FM, COSIMI LA, BADEN LR: Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. (2004) 350(9):950-952.
159. IMHOF A, BALAJEE SA, FREDRICKS DN, ENGLUND JA, MARR KA: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. (2004) 39(5):743-746.
160. MATTNER F, WEISSBRODT H, STRUEBER M: Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand. J. Infect. Dis. (2004) 36(4):312-314.
161. HERBRECHT RMK, CATANZARO A, GREENBERG R et al.: Posaconazole as salvage therapy for invasive fungal infections unresponsive to voriconazole: a cue series. 44th Interscience Conference on Antimicrobial agents and Chemotherapy, Washington, DC, USA (October 30 - November 2 2004).
162. MANAVATHU EK, CUTRIGHT JL, LOEBENBERG D, CHANDRASEKAR PH: A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J. Antimicrob. Chemother. (2000) 46(2):229-234.
163. MOSQUERA J, DENNING DW: Azole cross-resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. (2002) 46(2):556-557.
164. DENNING DW: Echinocandin antifungal drugs. Lancet (2003) 362(9390):1142-1151.
165. PFALLER MA, MESSER SA, BOYKEN L et al.: Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J. Clin. Microbiol. (2003) 41(12):5729-5731.
166. ERNST EJ, KLEPSER ME, ERNST ME, MESSER SA. PFALLER MA. Iv vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis. (1999) 33(2):75-90.
167. ERNST EJ, KLEPSER ME, PFALLER MA: Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44(4)-1108-1111.
168. BOWMAN JC, HICKS PS, KURTZ MB et al.: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. (2002) 46(9):3001-3012.
169. ULLMANN AJ, LIPTON JH, VESOLE DH et al: Posaconazole versus flucanazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft -versus-host disease. results of a multicenter trial. 45th International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (16 - 19 December 2005).
170. THIEBAUT SR A, ANTAL M, BREYSSE C, PIVOT C: Refractory invasive fungal infections in patients with hematologic malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B. 42nd Interscience Conference an Antimicrobial Agents and Chemotherapy San Diego, USA (27 - 30 September 2002).
171. MANAVATHU EK, ALANGADEN GJ, CHANDRASEKAR PH: Differential activity of triazoles in two-drug combinations with the echinorandin caspofungin against Aspergillus. J. Antimicrob. Chemother. (2003) 51(6):1423-1425.
172. PEREA S, GONZALEZ G, FOTHERGILL AW et al.: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. (2002) 46(9):3039-3041.
173. PETRAITIS V, PETRAITIENE R, SARAFANDI AA et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. (2003) 187(12):1834-1843.
174. SINGH N, LIMAYE A, SAFDAR N et al.: Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients. 45tb International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (16 - 19 December 2005).